Table 2.
MEFV mutations and concurrent disorders in FMF patients
| MEFV Mutation (+) (n=129) | Concurrent disorders | |
|---|---|---|
| Group I (n=73) | n=17 (23%)* | |
|
| ||
| M694V | 7 AMY | |
| -Hom | 2 BD | |
| -Het | 4 AS | |
| 1 APS | ||
| 1 HSP | ||
| 1 PsA+HSP+MPGN | ||
| 1 AS+AMY | ||
|
| ||
| Group II (n=56) | n=5 (8.9%) | |
|
| ||
| Other mutations | 1 AMY | |
| 1 BD | ||
| 1 AS | ||
| 1 UC | ||
| 1 Vitiligo | ||
*
p<0.04 Group I vs. Group II
Hom: homozygous; Het: heterozygous; AMY: amyloidosis; BD: Behcet’s disease; AS: ankylosing spondylitis; APS: antiphospholipid syndrome; HSP: Henoch–Schonlein purpura; PsA: psoriatic arthritis; MPGN: membranoproliferative glomerulonephritis; UC: ulcerative colitis